Abstract

ЕФЕКИ БЛОКАТОРА ТРИМЕТИЛАМІН-N-ОКСИДУ В ПОЄДНАННІ З АНТИХОЛІНЕСТЕРАЗНИМ ЗАСОБОМ У ХВОРИХ НА ЦУКРОВИЙ ДІАБЕТ 2-ГО ТИПУ

Highlights

  • Мета дослідження – оцінити ефективності Ипигриксу самостійно та у комбінації з Мілдронатом у пацієнтів із цукровим діабетом 2-го типу, що страждають на діабетичну полінейропатію, діабетичну енцефалопатію та ішемічну хворобу серця на тлі основного лікування

  • Materials and methods. 112 selected patients have been divided into 2 groups. 1st group patients, in addition to the basic therapy took Ipidacrine, while the 2nd group patients took a combination of Ipidacrine and Meldonium in addition to their basic treatment

  • Before and after add-on therapy, the following examinations were conducted: neurological research using the Neuropathy Disability Score (NDS) and endocrinological tests that included the examination of glucose and blood in the fasted state, the level of NOMA-IR index; measuring the level of microalbuminuria, creatinine of blood, glomerular filtration rate, glycated hemoglobin, cortisol and measuring lipid metavolism

Read more

Summary

Materials and methods

112 selected patients have been divided into 2 groups. 1st group patients, in addition to the basic therapy took Ipidacrine, while the 2nd group patients took a combination of Ipidacrine and Meldonium in addition to their basic treatment. 112 selected patients have been divided into 2 groups. 1st group patients, in addition to the basic therapy took Ipidacrine, while the 2nd group patients took a combination of Ipidacrine and Meldonium in addition to their basic treatment. The treatment course lasted for 1.5 month. Before and after add-on therapy, the following examinations were conducted: neurological research using the Neuropathy Disability Score (NDS) and endocrinological tests that included the examination of glucose and blood in the fasted state, the level of NOMA-IR index; measuring the level of microalbuminuria, creatinine of blood, glomerular filtration rate, glycated hemoglobin, cortisol and measuring lipid metavolism

Results and discussion
Conclusions
Лабораторні показники

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.